ANDA 207485, held by ABHAI. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 207485 (Methylphenidate Hydrochloride), held by ABHAI, was first approved by FDA on Nov 18, 2016, with 1 approved supplement and 0 published complete response letters.
1. INDICATIONS AND USAGE Methylphenidate hydrochloride oral solution is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older Narcolepsy Methylphenidate hydrochloride oral solution is a central nervous system (CNS) stimulant
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2016 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG/5ML · solution;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride10MG/5ML · solution;oral | Methylphenidate Hydrochloride | Rx |
| Jan 9, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 18, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters